Thermo Fisher to Sell Microbiology Business to Astorg for $1.075 Billion

What happened

Thermo Fisher Scientific signed a definitive agreement to sell its microbiology business to Astorg, a European private equity firm, for approximately $1.075 billion, consisting of cash and a $50 million seller note. The business, part of Thermo Fisher's Specialty Diagnostics segment, provides antimicrobial susceptibility testing and culture media solutions for clinical labs, pharmaceutical firms, and food safety testing. It generated $645 million in revenue in 2025, employs 2,400 people, and operates 13 manufacturing and R&D sites worldwide, serving over 15,000 customers across 38,000 labs in 100 countries with brands like Remel and Oxoid. The transaction is subject to regulatory approvals and is expected to close in the second half of 2026. Thermo Fisher anticipates the sale will be dilutive to adjusted earnings per share by $0.15 in the first full year following the close and will provide more details on the 2026 financial impact during its second quarter earnings call.

Why it matters

The divestiture represents Thermo Fisher's deliberate portfolio reshaping to focus on higher-growth, higher-margin biopharma services rather than mature diagnostics. CEO Marc Casper stated the transaction reflects active portfolio management and will provide additional capital for shareholder value creation, including potential acquisitions, share buybacks, or dividends. The sale follows recent major acquisitions in biopharma services, including $4.1 billion for Solventum's purification and filtration unit and $8.8 billion for Clario, which deliver better margins than the mature, commoditized microbiology testing market. For Astorg, the acquisition aligns with its healthcare investment strategy, representing 40% of its €8 billion portfolio, and offers an opportunity to build an independent diagnostics platform with recurring revenue streams from essential testing workflows. The business generates over 95% recurring revenue, providing stable cash flows attractive to private equity.

Bigger picture

Thermo Fisher's move reflects a broader industry trend of portfolio optimization, where large life sciences companies are shedding stable but slower-growth businesses to concentrate on higher-return segments. This mirrors recent strategic actions by peers: Johnson & Johnson announced plans to separate its orthopedics business in October, and Medtronic exited diabetes by creating standalone company MiniMed to focus on high-margin growth markets like pulsed-field ablation and renal denervation. Becton Dickinson also sold its $17.5 billion Biosciences & Diagnostic Solutions unit to Waters in July 2025. The shift contrasts with earlier mega-merger trends like Medtronic-Covidien and Abbott-St. Jude Medical, where companies pursued scale through expansion. Now, companies are getting smaller to grow faster, carving out mature operations and redirecting capital toward innovation-driven segments. Private equity firms like Astorg are capitalizing on this trend, acquiring profitable, cash-generative diagnostics assets with recurring revenue models and consolidating them into focused platforms.

What to watch

Investors should monitor Thermo Fisher's second quarter earnings call for detailed guidance on the transaction's impact on 2026 financial outlook and capital deployment plans. The regulatory approval process and actual closing timeline in the second half of 2026 will be key milestones. Watch for announcements on how proceeds are used, whether for further acquisitions in biopharma services, share buybacks under the existing $3 billion authorization, or dividends. Additionally, observe whether the company pursues further portfolio optimization or complementary bolt-on deals in high-growth areas like gene therapy and automation. For the microbiology business itself, monitor the transition under Astorg's ownership and any operational changes that could affect supply chains or customer relationships during the handoff period.

This article was generated by Quantli AI using publicly available news sources.